Campbell & CO Investment Adviser LLC acquired a new position in GlaxoSmithKline plc (NYSE:GSK) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 10,352 shares of the pharmaceutical company’s stock, valued at approximately $390,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in GSK. Marshall Wace North America L.P. purchased a new position in GlaxoSmithKline in the 1st quarter worth approximately $62,000. Deutsche Bank AG raised its holdings in GlaxoSmithKline by 8.3% in the 1st quarter. Deutsche Bank AG now owns 110,999 shares of the pharmaceutical company’s stock worth $4,205,000 after acquiring an additional 8,500 shares during the last quarter. Gabelli Funds LLC grew its position in GlaxoSmithKline by 23.7% in the 1st quarter. Gabelli Funds LLC now owns 53,450 shares of the pharmaceutical company’s stock worth $2,025,000 after purchasing an additional 10,250 shares during the period. Thrivent Financial for Lutherans bought a new stake in GlaxoSmithKline in the 1st quarter worth approximately $344,000. Finally, Balyasny Asset Management LLC bought a new stake in GlaxoSmithKline in the 1st quarter worth approximately $4,141,000. Institutional investors own 12.12% of the company’s stock.
A number of research firms have commented on GSK. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating and set a $41.00 target price for the company. in a research report on Tuesday, September 15th. Credit Suisse Group reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, October 5th. Morgan Stanley reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a research report on Friday, October 9th. Oddo Bhf raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 23rd. Finally, Societe Generale reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Friday, September 18th. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $41.00.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 29th. The pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.01). GlaxoSmithKline had a net margin of 19.03% and a return on equity of 31.21%. The business had revenue of $9.46 billion for the quarter, compared to the consensus estimate of $9.60 billion. Equities research analysts expect that GlaxoSmithKline plc will post 3.01 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Investors of record on Friday, August 14th were issued a $0.4914 dividend. The ex-dividend date was Thursday, August 13th. This represents a $1.97 annualized dividend and a yield of 5.38%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.47. GlaxoSmithKline’s dividend payout ratio is currently 61.20%.
In other news, Director Plc Glaxosmithkline bought 361,111 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The stock was bought at an average price of $18.00 per share, with a total value of $6,499,998.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 10.00% of the company’s stock.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.